Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020

Novo Nordisk obesity drugs Saxenda and Wegovy have sold for DKK 5.9bn (USD 919m) in the first three quarters of the year, surpassing the full-year sales last year.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Sales of Novo Nordisk's obesity drugs have continued their upward momentum, Wednesday's quarterly report from the pharmaceutical company shows.

According to the quarterly report, the obesity drug group, including the newly launched treatment Wegovy as well as its predecessor Saxenda, had a total revenue of 2.4bn (USD 373.7m) in the third quarter alone, corresponding to 79 percent compared to the same period last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs